This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About ATTR-CMAbout
ATTR-CMDisease ImpactWhen to Rule Out ATTR-CMDiagnosing ATTR-CMAbout VYNDAMAXAbout
VYNDAMAXMortality and Hospitalization6MWT/KCCQ-OS5-year DataHow VYNDAMAX WorksSafety Profile Study DesignDosingAccess & SupportAccess & SupportAccessing VYNDAMAXPaying for VYNDAMAXResourcesResourcesEventsMaterialsVideos
Prescribing InformationPatient InformationIndication Patient Site
Accessing VYNDAMAX

MEDICARE CHANGES FOR 2025: Medicare patients will pay no more than $2,000 total for all their Part D medications, including VYNDAMAX, for the full year of 2025.

Learn more about cost, coverage, and financial support

Patients can receive their medication
through either a National or eligible Outpatient
Specialty Pharmacy once you have
prescribed VYNDAMAXTwo ways to access:

National Specialty Pharmacy
Send your prescription to one of the National Specialty Pharmacies in the defined distribution network.*
See the list here

Outpatient Specialty Pharmacy, where applicable
Send your prescription to an eligible Outpatient Specialty Pharmacy.

*Access to VYNDAQEL® (tafamidis meglumine) is available through the same defined distribution network.
No matter which pathway you choose, prior authorization (PA) may be needed.
You can also submit a PA request at no cost through
www.CoverMyMeds.com
Pfizer Field Access Specialists (FAS) are available to provide additional education on how your patients can get access to VYNDAMAX. Ask your Pfizer representative to connect you with an FAS if you have questions about access, reimbursement, or financial support for your patients.
National coverage
  • Nationally, over 2/3 of claims paid by commercially insured patients were $50 or less per month for VYNDAMAX and VYNDAQEL® (tafamidis meglumine)
  • Nationally, more than 94% of Medicare Part D patients have access to VYNDAMAX after meeting applicable PA criteria
  • Nationally, Medicare patients eligible for the Low-Income Subsidy (LIS) program have access to VYNDAMAX for a co-pay of ≤$11.20 per prescription after meeting applicable PA criteria
See available resources to help navigate the post-prescription pathway.See moreLoadingNext: Learn about cost, coverage, and financial support options available to help your patients throughout treatmentContinueLoadingAccess & Support

Pfizer Field Access Specialists (FAS) can help providers understand the VYNDAMAX access journey
Ask your Pfizer representative to connect you with your local FAS

Pfizer Patient Access Coordinators (PACs) can help your patients during their treatment journey
All patients with a valid VYNDAMAX prescription are eligible to opt in

Request PAC SupportLoading
Access resources for you and your patient Explore resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-VDM-USA-1962
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-VDM-USA-0908
INDICATION AND LIMITATIONS OF USE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Please see Full Prescribing Information including Patient Information.
Important Safety InformationAdverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.IndicationVYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.